Latest Breaking News On - Innocan pharma ltd - Page 5 : vimarsana.com

InnoCan Pharma : MD&A report - 31 12 2021

INNOCAN PHARMA CORPORATION Management s Discussion and Analysis For the year ended December 31, 2021 1. MANAGEMENT S DISCUSSION AND. | April 24, 2022

Israel generalUnited statesChezy barenholzInternational financial reporting standardsInnocan pharma corporation the companyInnocan pharma corporationInnocan pharma ltdHebrew university of jerusalemCompany activity under research agreementsCanadian securities exchangeDescription of the company principal businessesTechnology transfer company of tel aviv universityTel aviv universityAnalysis forPharma corporationCanada business corporations acton may

Innocan Pharma s Case Report Accepted to the 25M Readers of Frontiers Veterinary Scientific Journal

Innocan Pharma s Case Report Accepted to the 25M Readers of Frontiers Veterinary Scientific Journal
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Israel generalTel avivHebrew universityIris bincovichChezy barenholzInnocan pharmaDevelopment company yissumCompany or innocanInnocan pharma corporationLiposome research departmentInnocan pharma ltdHebrew university of jerusalemAlberta newsfile corpTel aviv universityYissum researchPharma corporation

Innocan Pharma Corporation: Innocan Pharma s Case Report Accepted to the 25M Readers of Frontiers Veterinary Scientific Journal

Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - April 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to report the "accepted

Israel generalTel avivHebrew universityIris bincovichChezy barenholzInnocan pharmaDevelopment company yissumCompany or innocanInnocan pharma corporationLiposome research departmentInnocan pharma ltdHebrew university of jerusalemAlberta newsfile corpTel aviv universityYissum researchPharma corporation

Innocan Pharma Corporation: Innocan Pharma Reports a Successful FDA-Required Characterization of Highly CBD-Loaded Liposome Platform

Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - March 28, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to report the successful

Israel generalTel avivHebrew universityIris bincovichChezy barenholzInnocan pharmaDevelopment company yissumCompany or innocanInnocan pharma corporationLiposome research departmentInnocan pharma ltdHebrew university of jerusalemAlberta newsfile corpTel aviv universityYissum researchPharma corporation

Innocan Pharma Corporation: Innocan Pharma Reports a Positive Result from the Use of Its CBD LPT on a Dog Suffering from Osteoarthritis

Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - March 8, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that Innocan's

Israel generalTel avivHebrew universityIris bincovichChezy barenholzInnocan pharmaDevelopment company yissumCompany or innocanInnocan pharma corporationLiposome research departmentInnocan pharma ltdHebrew university of jerusalemInnocan liposome platform technologyAlberta newsfile corpTel aviv universityYissum research